Envestnet Asset Management Inc. lifted its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 20.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,587 shares of the biopharmaceutical company’s stock after buying an additional 2,313 shares during the period. Envestnet Asset Management Inc.’s holdings in Alexion Pharmaceuticals were worth $1,905,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Fiduciary Trust Co. acquired a new stake in Alexion Pharmaceuticals during the 2nd quarter worth $111,000. Penserra Capital Management LLC boosted its stake in Alexion Pharmaceuticals by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 144 shares during the period. Dupont Capital Management Corp acquired a new stake in Alexion Pharmaceuticals during the 3rd quarter worth $156,000. BT Investment Management Ltd acquired a new stake in Alexion Pharmaceuticals during the 3rd quarter worth $165,000. Finally, YorkBridge Wealth Partners LLC boosted its stake in Alexion Pharmaceuticals by 221.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,425 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 982 shares during the period. 94.33% of the stock is currently owned by hedge funds and other institutional investors.
ALXN has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price target for the company in a research note on Tuesday, October 31st. J P Morgan Chase & Co upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $163.00 to $175.00 in a research note on Tuesday, September 5th. Leerink Swann reiterated an “outperform” rating and set a $182.00 price target (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. They noted that the move was a valuation call. Credit Suisse Group reiterated a “buy” rating and set a $166.00 price target on shares of Alexion Pharmaceuticals in a research note on Tuesday, December 12th. Finally, Stifel Nicolaus decreased their price target on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating for the company in a research note on Tuesday, October 24th. Four investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $155.47.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $115.76 on Friday. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a market cap of $26,470.00, a price-to-earnings ratio of 23.13, a PEG ratio of 1.23 and a beta of 1.18. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The company had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. During the same quarter last year, the business earned $1.23 EPS. The business’s revenue was up 7.5% on a year-over-year basis. equities research analysts expect that Alexion Pharmaceuticals, Inc. will post 4.82 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Position Lifted by Envestnet Asset Management Inc.” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://transcriptdaily.com/2017/12/17/alexion-pharmaceuticals-inc-alxn-position-lifted-by-envestnet-asset-management-inc.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.